期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 97, 期 1, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2020.115012
关键词
cefiderocol; multidrug-resistant; carbapenem-resistant; Gram-negative bacilli
资金
- University of Manitoba
- Shionogi Co., Ltd.
- Shared Health
The in vitro activity of cefiderocol was evaluated against Gram-negative bacilli isolated from patients in Canadian intensive care units from 2015 to 2017 using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method and interpretive criteria. All 800 isolates of Gram-negative bacilli tested were susceptible to cefiderocol (MIC <= 4 mu g/ml), including isolates of ESBL-producing (n=40), AmpC-producing (n=6), and carbapenem-nonsusceptible (n=21) Enterobacterales. carbapenem-nonsusceptible (n=54) and multidrugresistant (n=29) Pseudomonas aeruginosa, Stenotrophomonas maltophilia (n=66), and Acinetobacter baumannii (n=11). (C) 2020 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据